BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Feb. 14, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Colorado on behalf of certain purchasers of shares of Clovis Oncology Inc (NASDAQ:CLVS) over alleged Securities Laws Violations by Clovis Oncology.
Investors who purchased shares of Clovis Oncology Inc (NASDAQ:CLVS) before May 2014 and continue to hold any NASDAQ:CLVS shares have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
On November 19, 2015, a lawsuit was filed against Clovis Oncology Inc over alleged securities laws violations. The plaintiff claimed that the defendants allegedly made false and misleading statements and/or failed to disclose that the NDA that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates, that Clovis Oncology’s Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses, that Clovis Oncology presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses, that as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected, and that as a result of the foregoing, Clovis Oncology’s NDA was likely to be delayed and/or rejected by the FDA. On July 27, 2016, the defendants filed their motions to dismiss the case. On February 9, 2017, the judge presiding over the case refused to dismiss the lawsuit.
Those who purchased Clovis Oncology Inc (NASDAQ:CLVS) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
